Nirmatrelvir
| Clinical data | |
|---|---|
| Pronunciation | /nɜːrˈmætrəlvɪər/ nur-MAT-rəl-veer or /ˌnɜːrməˈtrɛlvɪər/ NUR-mə-TREL-veer |
| Other names | PF-07321332 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | By mouth |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C23H32F3N5O4 |
| Molar mass | 499.535 g·mol−1 |
| 3D model (JSmol) | |
| Melting point | 192.9 °C (379.2 °F) |
| |
| |
Nirmatrelvir is an antiviral medication developed by Pfizer which acts as an orally active 3C-like protease inhibitor. It is part of a nirmatrelvir/ritonavir combination used to treat COVID-19 and sold under the brand name Paxlovid.